221050-88-0

Basic information

• Product Name: tert-Butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate
• Synonyms: tert-Butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate;1-Boc-4-(2-chloropyrimidin-4-yl)piperazine;2-Chloro-4-(4-Boc-1-piperazinyl)pyriMidine;2-Chloro-4-[1-(4-tert-butoxycarbonyl)piperazinyl]pyrimidine;4-(2-Chloropyrimidin-4-yl)piperazine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(2-Chloro-4-pyrimidinyl)-1-piperazinecarboxylate;tert-Butyl 4-(2-chloropyrimidin-4-yl)
• CAS NO: 221050-88-0
• Molecular Formula: C₁₃H₁₉ClN₄O₂
• Molecular Weight: 298.77
• Product Categories: pharmacetical
• Mol File: 221050-88-0.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 451.8ºC at 760 mmHg
• Flash Point: 227ºC
• Appearance: /
• Density: 1.253g/cm3
• Vapor Pressure: 2.37E-08mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.51±0.31(Predicted)
• CAS DataBase Reference: tert-Butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate(221050-88-0)
• EPA Substance Registry System: tert-Butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate(221050-88-0)

Safety Data

• Hazardous Substances Data: 221050-88-0(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate is a chemical compound with the molecular formula C14H20ClN3O2. It is a piperazine derivative that contains a tert-butyl group and a chloropyrimidine moiety. tert-Butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate is commonly used in medicinal chemistry as a building block for the synthesis of various pharmaceuticals, such as antipsychotic and antihistaminic drugs. It has also been investigated for its potential use as an anti-tumor agent. Tert-butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate is a versatile and important compound in the field of drug discovery and development.

InChI:InChI=1/C13H19ClN4O2/c1-13(2,3)20-12(19)18-8-6-17(7-9-18)10-4-5-15-11(14)16-10/h4-5H,6-9H2,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 7461-50-9 2-chloropyrimidin-4-amine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 3934-20-1 2,6-Dichloropyrimidine 

Downstream Products

• 479691-58-2 4-[2-(3-chloro-benzylamino)-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester 
• 479690-80-7 4-[2-(3,5-difluoro-benzyloxy)-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester 
• 1143576-96-8 tert-butyl 4-[2-(2,3-difluorophenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1143578-22-6 tert-butyl 4-(2-phenylpyrimidin-4-yl)piperazine-1-carboxylate 
• 1143576-85-5 tert-butyl 4-[2-(2,4-difluorophenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1092569-07-7 tert-butyl 4-[2-(3-hydroxymethylphenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1323917-69-6 2-(2-fluoro-phenyl)-4-{5-[4-(4-methyl-piperazin-1-yl)-pyrimidin-2-yl]-pyridin-3-yl}-[1,8]naphthyridine 
• 1323917-70-9 2-(2-fluoro-phenyl)-4-[5-(4-piperazin-1-yl-pyrimidin-2-yl)-pyridin-3-yl]-[1,8]naphthyridine 
• 1323920-03-1 C₃₂H₃₀FN₇O₂ 
• 1378368-15-0 tert-butyl 4-(2-(3-(tert-butyl)-4-(cyclopentylamino)phenyl)pyrimidin-4-yl)piperazine-1-carboxylate 
• 1143577-38-1 tert-butyl 4-[6-(2,4-difluorophenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1143577-39-2 4-(2,4-difluorophenyl)-6-(piperazin-1-yl)pyrimidine 
• 1143577-41-6 4-[6-(2,4-difluorophenyl)pyrimidin-4-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide 
• 1143576-86-6 2-(2,4-difluorophenyl)-4-(piperazin-1-yl)pyrimidine 

Relevant articles and documents

GLP-1R AGONISTS AND USES THEREOF

Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

UR-DEBa176: A 2,4-Diaminopyrimidine-Type Radioligand Enabling Binding Studies at the Human, Mouse, and Rat Histamine H4 Receptors

Differences in sequence homology between human (h), mouse (m), and rat (r) histamine H4 receptors (H4R) cause discrepancies regarding affinities, potencies, and/or efficacies of ligands and therefore compromise translational animal models and the applicability of radioligands. Aiming at a radioligand enabling robust and comparative binding studies at the h/m/rH4Rs, 2,4-diaminopyrimidines were synthesized and pharmacologically investigated. The most notable compounds identified were two (partial) agonists with comparable potencies at the h/m/rH4Rs: UR-DEBa148 (N-neopentyl-4-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-2-amine bis(2,2,2-trifluoroacetate), 43), the most potent [pEC50 (reporter gene assay) = 9.9/9.6/10.3] compound in the series being slightly G-protein biased and UR-DEBa176 [(R)-4-[3-(dimethylamino)pyrrolidin-1-yl]-N-neopentylpyrimidin-2-amine bis(2,2,2-trifluoroacetate), 46, pEC50 (reporter gene assay) = 8.7/9.0/9.2], a potential "cold" form of a tritiated H4R ligand. After radiolabeling, binding studies with [3H]UR-DEBa176 ([3H]46) at the h/m/rH4Rs revealed comparable Kd values (41/17/22 nM), low nonspecific binding (11-17%, aKd), and fast associations/dissociations (25-30 min) and disclosed [3H]UR-DEBa176 as useful molecular tool to determine h/m/rH4R binding affinities for H4R ligands.

2 - Amino pyrimidine compounds and their use (by machine translation)

The invention belongs to the technical field of pharmaceutical chemical synthesis, relates to the general formula (I) indicated by the 2 - amino pyrimidine compounds and their pharmaceutically acceptable salt, solvate or prodrug, their method of preparation and containing pharmaceutical composition of said compound, wherein substituent R1 , R2 , R6 With the meanings given in the specification. The invention also relates to the compounds of the formula I or its pharmaceutical composition for treating and/or preventing malignant blood diseases or other proliferative diseases in the use of the medicament. (by machine translation)